Non-alcoholic fatty liver disease: Diagnosis and investigation

Digestive Diseases

Volumn 32, Issue 5, 2014, Pages 586-596

  Nascimbeni, Fabio ^a   Loria, Paola ^a   Ratziu, Vlad ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Comorbidities; Diagnosis; Liver biopsy; Non alcoholic fatty liver disease; Non invasive methods

Indexed keywords

ALGORITHM; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROGNOSIS; COMORBIDITY; LIVER; LIVER CIRRHOSIS; MASS SCREENING; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; ACOUSTIC RADIATION FORCE IMPULSE IMAGING; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; CONFERENCE PAPER; CONSULTATION; DIAGNOSTIC VALUE; ECHOGRAPHY; ELASTOGRAPHY; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC MARKER; HIGH RISK PATIENT; INCIDENTAL FINDING; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER FUNCTION TEST; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRACTICE GUIDELINE; SCREENING TEST; STAGING;

COMORBIDITY; HUMANS; LIVER; LIVER CIRRHOSIS; MASS SCREENING; NON-ALCOHOLIC FATTY LIVER DISEASE;

AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

EID: 84904683671     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000360510     Document Type: Article

References (122)

1. Loria P, Adinolfi LE, Bellentani S, et al: Practice guidelines for the diagnosis and management of non-alcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010; 42: 272-282.
2. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
3. Chalasani N, Younossi Z, Lavine JE, et al: The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
4. Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43:S99-S112.
5. Kotronen A, Yki-Jarvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27- 38.
6. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G: From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-330.
7. Hui JM, Kench JG, Chitturi S, et al: Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-427.
8. Sanyal AJ, Banas C, Sargeant C, et al: Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-689.
9. Bhala N, Angulo P, van der Poorten D, et al: The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216.
10. Clouston AD, Jonsson JR, Powell EE: Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis 2007; 11: 173-189, x.
11. Powell EE, Jonsson JR, Clouston AD: Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis 2010; 28: 186-191.
12. Teli MR, James OF, Burt AD, Bennett MK, Day CP: The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719.
13. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
14. Soderberg C, Stal P, Askling J, et al: Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
15. Musso G, Gambino R, Cassader M, Pagano G: Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
16. Adams LA, Lymp JF, St Sauver J, et al: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
17. Wong VW, Wong GL, Tsang SW, et al: High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011; 60: 829-836.
18. Aron-Wisnewsky J, Minville C, Tordjman J, et al: Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012; 56: 225-233.
19. Reddy SK, Marsh JW, Varley PR, et al: Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatology 2012; 56: 2221-2230.
20. Youssef NA, Abdelmalek MF, Binks M, et al: Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int 2013; 33: 1062-1070.
21. Bonora E, Targher G: Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9: 372-381.
22. Armstrong MJ, Adams LA, Canbay A, Syn WK: Extra-hepatic complications of nonalcoholic fatty liver disease. Hepatology 2013, Epub ahead of print.
23. Newton JL: Systemic symptoms in non-alcoholic fatty liver disease. Dig Dis 2010; 28: 214- 219.
24. Machado M, Marques-Vidal P, Cortez-Pinto H: Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600-606.
25. Targher G, Bertolini L, Padovani R, et al: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218.
26. Targher G, Day CP, Bonora E: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
27. Mofrad P, Contos MJ, Haque M, et al: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
28. Browning JD, Szczepaniak LS, Dobbins R, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
29. Fracanzani AL, Valenti L, Bugianesi E, et al: Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-798.
30. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R: NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007; 46: 700-707.
31. Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM: Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev 2013; 34: 84-129.
32. Baumeister SE, Volzke H, Marschall P, et al: Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134: 85-94.
33. Nascimbeni F, Pais R, Bellentani S, et al: From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-871.
34. Palmentieri B, de Sio I, La Mura V, et al: The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006; 38: 485-489.
35. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ: Validity of realtime ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51: 1061-1067.
36. Machado MV, Cortez-Pinto H: Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58: 1007- 1019.
37. Hamaguchi M, Kojima T, Itoh Y, et al: The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-2715.
38. Ballestri S, Lonardo A, Romagnoli D, et al: Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012; 32: 1242-1252.
39. Xia MF, Yan HM, He WY, et al: Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring) 2012; 20: 444-452.
40. Szczepaniak LS, Nurenberg P, Leonard D, et al: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-E468.
41. Bedogni G, Bellentani S, Miglioli L, et al: The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
42. Poynard T, Ratziu V, Naveau S, et al: The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10.
43. Poynard T, Lassailly G, Diaz E, et al: Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta-analysis of individual patient data. PLoS One 2012; 7:e30325.
44. Kotronen A, Peltonen M, Hakkarainen A, et al: Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137: 865-872.
45. De Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B: Non-invasive diagnosis of liver steatosis using controlled attenuation parameter and transient elastography. Liver Int 2012; 32: 911-918.
46. Verma S, Jensen D, Hart J, Mohanty SR: Predictive value of ALT levels for non-alcoholic steatohepatitis and advanced fibrosis in nonalcoholic fatty liver disease. Liver Int 2013; 33: 1398-1405.
47. Prati D, Taioli E, Zanella A, et al: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
48. Dushay J, Chui PC, Gopalakrishnan GS, et al: Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 456-463.
49. Yilmaz Y, Eren F, Yonal O, et al: Increased serum FGF 21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010; 40: 887-892.
50. Li H, Fang Q, Gao F, et al: Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010; 53: 934-940.
51. Li H, Dong K, Fang Q, et al: High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol 2013; 58: 557-563.
52. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP: Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-597.
53. Patton HM, Patel K, Behling C, et al: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-490.
54. Leandro G, Mangia A, Hui J, et al: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
55. Loria P, Lonardo A, Leonardi F, et al: Nonorgan- specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003; 48: 2173-2181.
56. Vuppalanchi R, Gould RJ, Wilson LA, et al: Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2013, Epub ahead of print.
57. Muniyappa R, Lee S, Chen H, Quon MJ: Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294:E15-E26.
58. Bellentani S, Scaglioni F, Marino M, Bedogni G: Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161.
59. Kim D, Kim WR, Kim HJ, Therneau TM: Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-1365.
60. Treeprasertsuk S, Bjornsson E, Enders F, Suwanwalaikorn S, Lindor KD: NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013; 19: 1219- 1229.
61. Perazzo H, Munteanu M, Ngo Y, et al: Tenyear prognostic value of FibroTest and SteatoTest for liver-related and cardiovascular death in patients with type-2 diabetes and/or hyperlipidemia J Hepatol 2013; 58:S9-S10.
62. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
63. Kleiner DE, Brunt EM, Van Natta M, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
64. Sanyal AJ, Brunt EM, Kleiner DE, et al: Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-353.
65. Bedossa P, Poitou C, Veyrie N, et al: Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751-1759.
66. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD: Liver biopsy. Hepatology 2009; 49: 1017-1044.
67. Ratziu V, Charlotte F, Heurtier A, et al: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
68. Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
69. Ratziu V, Giral P, Charlotte F, et al: Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
70. Marchesini G, Bugianesi E, Forlani G, et al: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
71. Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV: Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 1222- 1224.
72. Loomba R, Abraham M, Unalp A, et al: Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943- 951.
73. Kowdley KV, Belt P, Wilson LA, et al: Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77-85.
74. Alkhouri N, Morris-Stiff G, Campbell C, et al: Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2012; 32: 297-302.
75. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
76. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA: Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006; 26: 151-156.
77. Poynard T, Ratziu V, Charlotte F, et al: Diagnostic value of biochemical markers (NashTest) for the prediction of non-alcoholo- steato-hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34.
78. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP: Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007; 102: 399-408.
79. Shimada M, Kawahara H, Ozaki K, et al: Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007; 102: 1931-1938.
80. Campos GM, Bambha K, Vittinghoff E, et al: A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47: 1916-1923.
81. Younossi ZM, Jarrar M, Nugent C, et al: A novel diagnostic biomarker panel for obesityrelated nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-1437.
82. Anty R, Iannelli A, Patouraux S, et al: A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32: 1315-1322.
83. Sumida Y, Yoneda M, Hyogo H, et al: A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 257- 268.
84. Tamimi TI, Elgouhari HM, Alkhouri N, et al: An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011; 54: 1224- 1229.
85. Younossi ZM, Page S, Rafiq N, et al: A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011; 21: 431-439.
86. Cusi K, Chang Z, Harrison S, et al: Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). J Hepatol 2014; 60: 167-174.
87. Tanwar S, Trembling PM, Guha IN, et al: Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology 2013; 57: 103-111.
88. Rosenberg WM, Voelker M, Thiel R, et al: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713.
89. Ratziu V, Massard J, Charlotte F, et al: Diagnostic value of biochemical markers (FibroTest- FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6.
90. Angulo P, Hui JM, Marchesini G, et al: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
91. Guha IN, Parkes J, Roderick P, et al: Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-460.
92. Cales P, Laine F, Boursier J, et al: Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165-173.
93. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA: Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447.
94. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP: Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269.
95. Adams LA, George J, Bugianesi E, et al: Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26: 1536-1543.
96. Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
97. Angulo P, Bugianesi E, Bjornsson ES, et al: Simple noninvasive systems predict longterm outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-789.e4.
98. Parkes J, Roderick P, Harris S, et al: Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-1251.
99. Vergniol J, Foucher J, Terrebonne E, et al: Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-1979, 1979.e1-3
100. Festi D, Schiumerini R, Marzi L, et al: Review article: the diagnosis of non-alcoholic fatty liver disease - availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013; 37: 392-400.
101. Wong VW, Vergniol J, Wong GL, et al: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462.
102. Myers RP, Pomier-Layrargues G, Kirsch R, et al: Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
103. De Ledinghen V, Wong VW, Vergniol J, et al: Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan ® . J Hepatol 2012; 56: 833-839.
104. Wong VW, Vergniol J, Wong GL, et al: Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107: 1862- 1871.
105. Castera L, Vilgrain V, Angulo P: Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 666-675.
106. Wong GL, Chan HL, Choi PC, et al: Association between anthropometric parameters and measurements of liver stiffness by transient elastography. Clin Gastroenterol Hepatol 2013; 11: 295-302.e1-3.
107. Wong GL, Vergniol J, Lo P, et al: Non-invasive assessment of liver fibrosis with transient elastography (FibroScan ® ): applying the cut-offs of M probe to XL probe. Ann Hepatol 2013; 12: 570-580.
108. Crespo G, Fernandez-Varo G, Marino Z, et al: ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol 2012; 57: 281- 287.
109. Yoneda M, Suzuki K, Kato S, et al: Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256: 640-647.
110. Palmeri ML, Wang MH, Rouze NC, et al: Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55: 666- 672.
111. Friedrich-Rust M, Romen D, Vermehren J, et al: Acoustic radiation force impulse-imaging and transient elastography for noninvasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81:e325-e331.
112. Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C: Accuracy of real-time ShearWave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 2012; 56: 2125-2133.
113. Poynard T, Munteanu M, Luckina E, et al: Liver fibrosis evaluation using real-time ShearWave elastography: applicability and diagnostic performance using methods without a gold standard. J Hepatol 2013; 58: 928-935.
114. Romeo S, Kozlitina J, Xing C, et al: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
115. Sookoian S, Pirola CJ: Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894.
116. Kumashiro N, Yoshimura T, Cantley JL, et al: Role of patatin-like phospholipase domain- containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology 2013; 57: 1763-1772.
117. Loria P, Lonardo A, Anania F: Liver and diabetes. A vicious circle. Hepatol Res 2013; 43: 51-64.
118. Loria P, Carulli L, Bertolotti M, Lonardo A: Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6: 236-247.
119. Moon SS, Lee YS, Kim SW: Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine 2012; 42: 423-429.
120. Sookoian S, Pirola CJ: Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg 2013; 23: 1815-1825.
121. Newton JL, Jones DE, Henderson E, et al: Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57: 807-813.
122. McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA: Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched casecontrol study. Ann Surg 2007; 245: 923-930.